Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2 Randomized Double-Blind Placebo-Controlled Trial to Evaluate the Efficacy and Safety of BHV-4157 in Patients With Mild to Moderate Alzheimer's Disease

Trial Profile

A Phase 2 Randomized Double-Blind Placebo-Controlled Trial to Evaluate the Efficacy and Safety of BHV-4157 in Patients With Mild to Moderate Alzheimer's Disease

Status: Active, no longer recruiting
Phase of Trial: Phase II/III

Latest Information Update: 08 Nov 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Troriluzole (Primary)
  • Indications Alzheimer's disease
  • Focus Therapeutic Use
  • Acronyms T2 Protect AD
  • Sponsors Biohaven Pharmaceutical; Biohaven Pharmaceutical Holding Company
  • Most Recent Events

    • 05 Nov 2019 According to a Biohaven Pharmaceutical media release, an interim futility analysis results expected in the fourth quarter of 2019 (end of this year).
    • 05 Nov 2019 Status changed from recruiting to active, no longer recruiting.
    • 25 Oct 2019 Planned number of patients changed from 292 to 336.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top